Form 8-K - Current report:
SEC Accession No. 0001193125-24-248760
Filing Date
2024-10-31
Accepted
2024-10-31 16:45:59
Documents
16
Period of Report
2024-10-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d901554d8k.htm   iXBRL 8-K 39643
2 EX-10.1 d901554dex101.htm EX-10.1 112781
3 EX-99.1 d901554dex991.htm EX-99.1 12911
7 GRAPHIC g901554g1031073810040.jpg GRAPHIC 2206
  Complete submission text file 0001193125-24-248760.txt   328822

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA lyel-20241031.xsd EX-101.SCH 2845
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20241031_lab.xml EX-101.LAB 17236
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20241031_pre.xml EX-101.PRE 10809
18 EXTRACTED XBRL INSTANCE DOCUMENT d901554d8k_htm.xml XML 3508
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 241415848
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)